AR006892A1 - USE OF FORMS OF HYALURONIC ACID (HA) FOR THE TREATMENT OF CANCER - Google Patents
USE OF FORMS OF HYALURONIC ACID (HA) FOR THE TREATMENT OF CANCERInfo
- Publication number
- AR006892A1 AR006892A1 ARP970101754A ARP970101754A AR006892A1 AR 006892 A1 AR006892 A1 AR 006892A1 AR P970101754 A ARP970101754 A AR P970101754A AR P970101754 A ARP970101754 A AR P970101754A AR 006892 A1 AR006892 A1 AR 006892A1
- Authority
- AR
- Argentina
- Prior art keywords
- hyaluronic acid
- treatment
- cancer
- forms
- diluent
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 4
- 229920002674 hyaluronan Polymers 0.000 title abstract 4
- 229960003160 hyaluronic acid Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Se provee un método para el tratamiento del cáncer que comprende la administración por vía oral o sistémica (preferentemente intravenosa) de unacantidad dosificada efectiva de una forma del ácido hialurónico seleccionado del grupo que consiste de ácido hialurónico y las salesfarmacéuticamente aceptables del mismo como único agente terapéutico activo, en un diluyente, en cantidades tales y durante el tiempo suficientes como parapermitir un tratamiento exitoso del cáncer.A method for the treatment of cancer is provided which comprises the oral or systemic administration (preferably intravenous) of an effective dosed amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and the pharmaceutically acceptable salts thereof as the sole therapeutic agent. active, in a diluent, in amounts such and for a time sufficient to permit successful cancer treatment.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002175282A CA2175282A1 (en) | 1996-04-29 | 1996-04-29 | Use of forms of hyaluronic acid (ha) for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR006892A1 true AR006892A1 (en) | 1999-09-29 |
Family
ID=4158095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970101754A AR006892A1 (en) | 1996-04-29 | 1997-04-29 | USE OF FORMS OF HYALURONIC ACID (HA) FOR THE TREATMENT OF CANCER |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR006892A1 (en) |
| AU (1) | AU2564497A (en) |
| CA (1) | CA2175282A1 (en) |
| WO (1) | WO1997040841A1 (en) |
| ZA (1) | ZA973622B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888984A (en) * | 1994-05-12 | 1999-03-30 | Dermal Research Laboratories, Inc. | Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| NZ512676A (en) | 1999-01-13 | 2003-01-31 | Meditech Res Ltd | A composition and method for the enhancement of the efficacy of drugs |
| CA2361268C (en) | 1999-02-01 | 2014-06-10 | Dermal Research Laboratories, Inc. | A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| AU3886600A (en) * | 1999-03-15 | 2000-10-04 | Trustees Of Boston University | Angiogenesis inhibition |
| US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
| AUPQ879500A0 (en) * | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| AU760404B2 (en) * | 2000-07-14 | 2003-05-15 | Alchemia Oncology Pty Limited | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| US7879824B2 (en) | 2001-07-31 | 2011-02-01 | Dermal Research Laboratories, Inc. | Methods of preventing or treating diseases and conditions using complex carbohydrates |
| CA2417867C (en) * | 2000-07-31 | 2012-09-11 | Dermal Research Laboratories, Inc. | Methods of preventing or treating diseases and conditions using complex carbohydrates |
| AU2002325635C1 (en) * | 2001-08-27 | 2008-09-25 | Alchemia Oncology Pty Limited | Improved therapeutic protocols |
| US20050042303A1 (en) * | 2001-08-27 | 2005-02-24 | Brown Tracey Jean | Therapeutic protocols |
| ITPD20020271A1 (en) | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | CHEMICAL-PHARMACEUTICAL COMPOUNDS CONSISTING OF TAXAN DERIVATIVES COVALENTLY LINKED TO HYALURONIC ACID OR ITS DERIVATIVES. |
| AU2006274509B2 (en) | 2005-07-27 | 2012-01-19 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| BRPI0615619A2 (en) | 2005-09-07 | 2011-05-24 | Alchemia Oncology Pty Ltd | therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
| US9375447B2 (en) * | 2013-03-14 | 2016-06-28 | National Cheng Kung University | Modified hyaluronan and uses thereof in cancer treatment |
| CN105311051A (en) | 2014-05-26 | 2016-02-10 | 陈松源 | Carrier solvent having antitumor drug treatment effect increasing function, preparation method and administration route thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6117A (en) * | 1984-06-11 | 1986-01-06 | Seikagaku Kogyo Co Ltd | Mucopolysaccharide-type cancer-metastatis suppressing agent |
| US5262403A (en) * | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
| CA2067211C (en) * | 1990-07-24 | 2004-06-15 | Katsukiyo Sakurai | Phospholipid- or lipid-linked glycosaminoglycan, process for producing the same and metastasis inhibitor |
| CA2122519C (en) * | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
| WO1994020115A2 (en) * | 1993-03-10 | 1994-09-15 | Miles, Inc. | Hyaluronic acid used as a cancer treatment |
-
1996
- 1996-04-29 CA CA002175282A patent/CA2175282A1/en not_active Abandoned
-
1997
- 1997-04-25 ZA ZA9703622A patent/ZA973622B/en unknown
- 1997-04-28 WO PCT/CA1997/000283 patent/WO1997040841A1/en not_active Ceased
- 1997-04-28 AU AU25644/97A patent/AU2564497A/en not_active Abandoned
- 1997-04-29 AR ARP970101754A patent/AR006892A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2564497A (en) | 1997-11-19 |
| CA2175282A1 (en) | 1997-10-30 |
| ZA973622B (en) | 1997-11-25 |
| WO1997040841A1 (en) | 1997-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR006892A1 (en) | USE OF FORMS OF HYALURONIC ACID (HA) FOR THE TREATMENT OF CANCER | |
| ES2074124T3 (en) | COMPOSITION IN THE FORM OF A FOAM CONTAINING 5-AMINOSALICYLIC ACID FOR INTRA-RECTAL ADMINISTRATION. | |
| CR6656A (en) | DOSAGE FORM OF DRUGS DRIVEN BY A HYDROGEL | |
| MXPA01003182A (en) | SYSTEM OF CONTROLLED RELEASE OF ANTIFUNGIC AND KERATOLITIC AGENTS FOR THE LOCAL TREATMENT OF FUNGICAL INFECTIONS OF THE ONE AND THE CIRCUNDANT FABRICS. | |
| ES2094539T3 (en) | PHARMACEUTICAL PREPARATION AND PROCEDURE FOR ITS PREPARATION. | |
| CZ309247B6 (en) | 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour | |
| CO5060522A1 (en) | ADMINISTRATION OF AN ACTIVE AGENT IN AEROSOL | |
| AR020760A1 (en) | DEVICE FOR CONTROLLING THE ADMINISTRATION OF AN ACTIVE AGENT IN AEROSOL IN THE LUNGS OF A HUMAN PATIENT | |
| ES2077530B1 (en) | PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS TO CURE TUMOR DISEASES. | |
| ES2082288T3 (en) | THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF KETOROLACO. | |
| ES2063033T3 (en) | USE OF IGF-II IN THE TREATMENT OF BONE DISEASES. | |
| EE200200107A (en) | Use of a fast-acting selective serotonin reuptake inhibitor in the manufacture of a medicament for the treatment of sexual dysfunction | |
| PE28397A1 (en) | NON-INORGANIC SALINE SOLUTIONS FOR ENDONASAL ADMINISTRATION | |
| BR0109672A (en) | Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal | |
| AR032151A1 (en) | USE OF AN ANTI-ANGIOGENIC PHARMACO IN CONJUNCTION WITH A PHOTOSENSIBLE AGENT FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE IMPROVED PHOTODYNAMIC TREATMENT OF INDOVATED NEOVASCULATURE | |
| AR015744A1 (en) | USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY | |
| ES2125696T3 (en) | USE OF TROPSY CHLORIDE FOR THE PRODUCTION OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF VESIC DYSFUNCTIONS. | |
| ECSP045110A (en) | COMPOSITIONS OF THE PREPARATION CONTAINING A PHYSIOLOGICALLY ACTIVE COMPOSITE OF UNSTABLE ACIDS AND PROCESSES FOR THEIR PRODUCTION | |
| AR002743A1 (en) | NAIL ENAMEL, AND THE USE OF SUCH ENAMEL FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF ONYCHOMICOSIS. | |
| AR002027A1 (en) | TRANSDERMIC FORMULATIONS AND PROCESS TO PREPARE THEM. | |
| ES2099649T3 (en) | NEW PHARMACEUTICAL COMPOSITION INTENDED FOR THE MANUFACTURE OF A STABLE POWDER CONTAINING, AS A ACTIVE INGREDIENT, AN ASSOCIATION OF ACETYLSALICILIC ACID AND METOCLOPRAMIDE. | |
| DK1194109T3 (en) | Topical formulations comprising skin permeation agents and their use | |
| CO5271647A1 (en) | METHOD TO PREVENT DIARRHEA | |
| EE200200549A (en) | Split dose therapy with vascular damaging activity | |
| AR005724A1 (en) | BIOLOGICALLY ACTIVE UREID DERIVATIVES USEFUL IN THE TREATMENT OF MULTIPLE SCLEROSIS |